Imosphere provides OMOP consultancy to University of Edinburgh Cancer Informatics
Imosphere is delighted to be working with University of Edinburgh Cancer Informatics to provide consultancy and support for their project to map cancer registry data to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM), as part of the EHDEN project (European Health Data & Evidence Network).
The data mapping project involved data maintained by the Edinburgh Cancer Centre on behalf of the regional cancer service covering NHS Lothian, NHS Fife, NHS Dumfries and Galloway, and NHS Borders, serving a population of 1.5 million. It contains a broad spectrum of data items across various stages of the cancer patient journey, including diagnosis, treatment, follow-up and recurrence. Datasets from the ChemoCare reporting database, Scottish Morbidity Record, and COVID ilabs will also be used.
Through the EHDEN Harmonation Fund, University of Edinburgh Cancer Informatics approached Imosphere as an accredited EHDEN SME to provide consultancy and knowledge transfer of OMOP data mapping best practice and transformation techniques.
Peter Hall, Medical Oncologist at University of Edinburgh, commented, “Imosphere has brought its experience of other OMOP mapping and transformation projects and allowed us to accelerate our understanding of the OMOP CDM and build a relatable transformation. It has also been of great benefit to align our converted data to other institutions with similar data that Imosphere has worked with, which will greatly improve the quality and depth of research possible.”
Mark Rogers, Head of Service: Data and Analytics at Imosphere, commented, “We’re delighted to be able to provide consultancy to UoE for this project. Our support will help to ensure UoE are ready to be onboarded in the EHDEN and OHDSI data networks and participate in research studies, allowing them to collaborate on a national and international level.”
An EHDEN Project
This project forms part of a wider project by EHDEN, whose main objective is to address the current challenges in generating insights and evidence from real-world clinical data at scale, to support patients, clinicians, payers, regulators, governments, and the pharmaceutical industry in better understanding well-being, disease, treatments, outcomes and new therapeutics and devices through a federated network of many million patient data records.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.